Abstract:Chao Tian, 1, &ast Yanyan Yang, 2, &ast Bing Li, 3 Meixin Liu, 4 Xiangqin He, 4 Liang Zhao, 4 Xiaoxia Song, 4 Tao Yu, 4, 5 Xian-Ming Chu 1, 6 1 Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China; 2 Department of Immunology, Basic Medicine School, Qingdao University, Qingdao, People's Republic of China; 3 Department of Genetics, Basic Medicine School, Qingdao University, Qingdao, People's Republic of China; 4 Department of Cardiac Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China; 5 Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China; 6 Department of Cardiology, The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tao Yu, Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China, Tel/Fax +86-532-82991791, Email Xian-Ming Chu, Department of Cardiology, the Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, 266100, People's Republic of China, Tel +86-532-82913257, Email Purpose: To explore the therapeutic mechanism of bone marrow mesenchymal stem cells derived exosomes (BMSC-Exos) for doxorubicin (DOX)-induced cardiotoxicity (DIC) and identify the long noncoding RNAs' (lncRNAs') anti-inflammation function derived by BMSC-Exos. Materials and Methods: High-throughput sequencing and transcriptome bioinformatics analysis of lncRNA were performed between DOX group and BEC (bone marrow mesenchymal stem cells derived exosomes coculture) group. Elevated lncRNA (ElncRNA) in the cardiomyocytes of BEC group compared with DOX group were confirmed. Based on the location and co-expression relationship between ElncRNA and its target genes, we predicted two target genes of ElncRNA, named cis_targets and trans_targets. The target genes were analyzed by enrichment analyses. Then, we identified the key cellular biological pathways regulating DIC. Experiments were performed to verify the therapeutic effects of exosomes and the origin of lncRNAs in vitro and in vivo. Results: Three hundred and one lncRNAs were differentially expressed between DOX and BEC groups (fold change > 1.5 and p < 0.05), of which 169 lncRNAs were elevated in the BEC group compared with the DOX group. GO enrichment analysis of target genes of ElncRNAs showed that they were predominantly involved in inflammation-associated processes. KEGG analysis indicated that their regulatory pathways were mainly involved in oxidative stress-induced inflammation and proliferation of cardiomyocyte. The verification experiments in vitro showed that the oxidative stress and cell deaths were decreased in BEC groups. Moreover, from the top 10 ElncRNAs identified in the sequencing results, MSTRG.98097.4 and MSTRG.58791.2 were both decreased in the DOX group and elevated in BEC group. While in verification experiments in vivo, only the expression of MSTRG.58791.2 is consistent with the result in vitro. Conclusion: Our results show that ElncRNA, MSTRG.58791.2, is possibly secreted by the BMSC-Exos and able to alleviate DIC by suppressing inflammatory response and inflammation-related cell death. Keywords: doxorubicin-induced cardiotoxicity, exosomes, inflammation, transcriptome sequencing analysis The rapid development of immune checkpoint inhibitors and targeted therapy has advanced tumor therapy into a new era of precision medicine. Chemotherapy remains the cornerstone of oncological treatment. Doxorubicin (DOX), a variety of cross-sectional anthracycline, is indispensable in chemotherapy. However, it can also induce senescence, 1 apoptosis, 2 pyroptosis, 3 autophagy, 4 and ferroptosis 5 of cardiomyocytes, causing arrhythmia, hypertrophic cardiomyopathy, and congestive heart failure while killing tumor cells. 6 The cardiovascular damage associated with DOX chemotherapy, termed doxorubicin-induced cardiotoxicity (DIC), seriously threatens the health of cancer patients due to its progressive, irreversible nature. 7 At present, dexrazoxane (DZR) is recognized as the only drug to prevent DIC, but it has a limited effect and poses the risk of secondary tumors or bone marrow suppression. 8 Therefore, there is a need to find potential biomarkers and elucidate the molecular mechanism of DIC, which will benefit the exploration of effective targets f -Abstract Truncated-

Extracellular Vesicles Released after Doxorubicin Treatment in Rats Protect Cardiomyocytes from Oxidative Damage and Induce Pro-Inflammatory Gene Expression in Macrophages

Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury

Overexpression Of Vascular Endothelial Growth Factor 165 (Vegf(165)) Protects Cardiomyocytes Against Doxorubicin-Induced Apoptosis

Early Transcriptional Changes in Cardiac Mitochondria During Chronic Doxorubicin Exposure and Mitigation by Dexrazoxane in Mice.

Acetylcholinesterase inhibitor ameliorates doxorubicin-induced cardiotoxicity through reducing RIP1-mediated necroptosis

Small-molecule mediated MuRF1 inhibition protects from doxorubicin-induced cardiac atrophy and contractile dysfunction

Exosome Treatment Enhances Anti-Inflammatory M2 Macrophages and Reduces Inflammation-Induced Pyroptosis in Doxorubicin-Induced Cardiomyopathy

Resveratrol Attenuates Doxorubicin-Induced Cardiotoxicity in Rats by Up-Regulation of Vascular Endothelial Growth Factor B.

The mechanism and therapeutic strategies in doxorubicin-induced cardiotoxicity: Role of programmed cell death

Doxorubicin-Induced Cardiotoxicity May Be Alleviated by Bone Marrow Mesenchymal Stem Cell-Derived Exosomal lncRNA via Inhibiting Inflammation

Liposomal Resveratrol and/or Carvedilol Attenuate Doxorubicin-Induced Cardiotoxicity by Modulating Inflammation, Oxidative Stress and S100A1 in Rats

Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy

The effects of extracellular vesicles derived from Krüppel-Like Factor 2 overexpressing endothelial cells on the regulation of cardiac inflammation in the dilated cardiomyopathy

Enhanced therapeutic efficacy of SERCA2a gene-modified adipose-derived mesenchymal stem cell exosomes in doxorubicin-induced cardiomyopathy in male albino rats

Resolvin D1 Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Inflammation, Oxidative and Endoplasmic Reticulum Stress

1,25(OH)2D3 ameliorates doxorubicin‑induced cardiomyopathy by inhibiting the NLRP3 inflammasome and oxidative stress

Integration of transcriptomics, metabolomics, and lipidomics reveals the mechanisms of doxorubicin-induced inflammatory responses and myocardial dysfunction in mice

Everolimus prevents doxorubicin-induced apoptosis in H9c2 cardiomyocytes but not in MCF-7 cancer cells: Cardioprotective roles of autophagy, mitophagy, and AKT

Abstract P2179: Endothelial-derived Extracellular Vesicles Communicate With Cardiomyocytes To Elicit Cancer Therapy-related Cardiac Dysfunction

Preventive Cardioprotection of Erythropoietin Against Doxorubicin-Induced Cardiomyopathy.

Primary Protection of Diosmin Against Doxorubicin Cardiotoxicity via Inhibiting Oxido-Inflammatory Stress and Apoptosis in Rats